SCHEMBL10245720

SCHEMBL10245720

Cc1cc(C(=O)NC[C@H](NC(=O)c2ccc(Oc3ccccc3)cc2)C(=O)N[C@@H](CC(C)C)B(O)O)n(C)n1

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 11/20 0.49
KLKB1 P03952 1/20 0.44
PSMB8 P28062 1/20 0.43
PSMB9 P28065 1/20 0.43
CLPP Q16740 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10247685 0.84 PSMB5 (0.45) PSMB5KLKB1PSMB8PSMB9CLPP
SCHEMBL10191351 0.84 PSMB5 (0.59) PSMB5CLPP
SCHEMBL10191349 0.80 PSMB5 (0.56) PSMB5CLPP
SCHEMBL8295964 0.76 PSEN1 (0.62) PSMB5PSMB8PSMB9
SCHEMBL3161159 0.76 PSEN1 (0.62) PSMB5PSMB8PSMB9
SCHEMBL3159944 0.74 PSMB5 (0.58) PSMB5PSMB8PSMB9CLPP
SCHEMBL10246320 0.73 PSMB5 (0.52) PSMB5CLPP
SCHEMBL2927796 0.72 PSMB5 (0.53) PSMB5PSMB8PSMB9CLPP
SCHEMBL2932543 0.72 PSMB5 (0.53) PSMB5PSMB8PSMB9
SCHEMBL12829161 0.71 PSMB5 (0.56) PSMB5PSMB8PSMB9CLPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 US disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 US disclosed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885KLKB1 3180/4885PSMB8 20/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885KLKB1 3180/4885PSMB8 20/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885KLKB1 3180/4885PSMB8 20/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885KLKB1 3180/4885PSMB8 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.